Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Teva Pharmaceutical Industries Ltd. Earnings Release 2013

Dec 22, 2013

7082_rns_2013-12-22_35db26df-c89a-4388-8a4b-2118c8ddeae9.pdf

Earnings Release

Open in viewer

Opens in your device viewer

==> picture [252 x 64] intentionally omitted <==

Teva to Report Fourth Quarter 2013 Financial Results on February 6, 2014

Jerusalem, December 19, 2013 - Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that it will release its fourth quarter 2013 financial results on Thursday, February 6, 2014 at 7:00 a.m. ET.

Teva will host a conference call and live webcast on the same day, at 8:00 a.m. ET to discuss its fourth quarter 2013 results and overall business environment. A Question & Answer session will follow this discussion.

In order to participate, please dial the following numbers (at least 10 minutes before the scheduled start time): United States and Canada 1-888-895-5271; International 1-847-619-6547; passcode: 36341322.

A live webcast of the call will also be available on Teva's website at: www.tevapharm.com. Please log in at least 10 minutes prior to the conference call in order to download the applicable audio software.

Following the conclusion of the call, a replay of the webcast will be available within 24 hours on the Company's website. The replay can also be accessed until February 13, 2014, at 11:59 p.m. ET by calling 1-888-843-7419 or 1-630-652-3042; passcode: 36341322#.

About Teva

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world's leading generic drug maker, with a global product portfolio of more than 1,000 molecules and a direct presence in about 60 countries. Teva's branded businesses focus on CNS, oncology, pain, respiratory and women's health therapeutic areas as well as biologics. Teva currently employs approximately 46,000 people around the world and reached $20.3 billion in net revenues in 2012.

IR Contacts: Kevin C. Mannix Ran Meir Tomer Amitai

United States United States Israel

(215) 591-8912 (215) 591-3033 972 (3) 926-7656

PR Contacts: Iris Beck Codner Denise Bradley

972 (3) 926-7246 (215) 591-8974

Israel United States